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tal cost-effectiveness based on a decision tree to simulate the costs of treatment,
with a time horizon of 12 months (nominal cost).The monthly dose of erythropoi-
esis stimulating agents was adjusted according to hemoglobin levels, if the con-
centration is greater than 12.5 g/dl 10.000 IU/month of erythropoietin beta or 0.6
mcg/kg/month of MPG-beta, for 11 -12.5 g/dl 20.000 IU/month of erythropoietin
beta or 1.2 mcg/kg/month of MPG-beta and concentrations below 11 g/dl 40.000
IU/month of erythropoietin beta or 1.5 mcg/kg/month of MPG-beta. Each scenario
has a cost based on usual care of these patients. The direct costs were taken from
the current rates for 2010 apply to medical services provided by IMSS. We deter-
mined the risk of not being in an ideal range of hemoglobin (11-12.5 g/dl), also
known as hemoglobin excursions and associated costs. RESULTS:MPG-beta main-
tains a more stable hemoglobin concentration when compared with erythropoietin
beta, so that at 6 months of treatment remain in the ideal range 94% versus 80%
with erythropoietin beta. With the use of erythropoietin beta there is a greater risk
of having excursions. The incremental cost-effectiveness analysis shows a 13%
increase in effectiveness for only an additional $30 USD annually using MPG-beta
compared with erythropoietin beta, this derived from the stability of hemoglobin.
The ICER is $2.3 USD per incremental percentage of effectiveness. CONCLUSIONS:
These results demonstrate that MPG-beta offers better health outcomes against an
almost insignificant cost increase being as a cost effective treatment.
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OBJECTIVES: To carry out a cost-utility analysis comparing initial treatment with
solifenacin 5 mg/day versus oxybutynin immediate-release (IR) 15 mg/day for the
treatment of patients with overactive bladder (OAB) from the perspective of the UK
National Health Service (NHS). METHODS: A Markov model with six health states
was developed in EXCEL to follow a cohort of OAB patients treated with either
solifenacin or oxybutynin during a one year period. Costs and utilities were accu-
mulated as patients transited through the health states in the model including a
drop-out state. Some of the solifenacin patients were titrated from 5mg to 10mg/
day at 8 weeks. A proportion of drop-out patients were assumed to continue treat-
ment with tolterodine ER. Utility values were obtained from a Swedish study and
pad use was based on a multinational clinical trial. Adherence rates for individual
treatments were derived from a UK database study. For pad use and utility values,
the drop-out state was split between those patients who were no longer receiving
treatment and those on second-line therapy. Patients on second-line therapy who
drop-out were referred for a specialist visit. Results were expressed in terms of
incremental cost-utility ratios. RESULTS: Total annual costs for solifenacin and
oxybutynin were £504.30 and £414.10 respectively. First-line drug use represents
49% and 16% of costs and pad use represent 23% and 35% of costs for solifenacin
and oxybutynin respectively. Differences between cumulative utilities were small
but were greater for solifenacin (0.7020 vs. 0.6907). The baseline incremental cost-
effectiveness ratio was £7,921/QALY. CONCLUSIONS: Under our baseline assump-
tions, solifenacin is cost-effective with an incremental cost-utility of less than
£20,000/QALY. However, small differences in utility between the alternatives and
the large number of drop-outs means that the results are sensitive to small adjust-
ments in the values of utilities assigned to the drop-out state.
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OBJECTIVES: To compare 1-year treatment cost of initial continuous renal replace-
ment therapy (CRRT) vs. intermittent daily hemodialysis (IHD) or slow extended
daily dialysis (SLEDD) in critically ill patients with acute renal failure in Germany.
METHODS: As differences in hospital survival rates among the evaluated renal
replacement therapies (RRT) are not evident, a cost-minimization model was de-
veloped to compute potential direct medical costs associated with dialysis for each
treatment group. The preliminary analysis has been performed from the perspec-
tive of the German statutory health insurance. Model input data was derived from
published literature and complemented by expert opinion in case of missing
information. RESULTS: Total estimated average per-patient hospital costs were
found to be similar for the evaluated hypothetical RRT cohorts, amounting to
€12,380 for CCRT, €12,650 for IHD, and €12,528 for SLEDD. Whereas costs of dispos-
ables are substantially higher for CRRT than for IHD/SLEDD, these incremental
costs were largely offset by an expected average ICU stay reduction of one day
owing to assumed minor treatment benefits for CRRT. As sufficiently powered,
randomized comparative trials are currently lacking, we assumed equivalent hos-
pital mortality for each analyzed RRT treatment group as shown in meta-analyses,
but a slightly higher renal recovery rate at discharge for CRRT than for IHD/SLEDD
(87.8% vs. 80.0%) as indicated by several studies. Consequently, follow-up costs
involving chronic RRT in survivors remaining dialysis dependent after discharge
were lower for CRRT than for IHD/SLEDD resulting in total first year average per-
patient costs of €14,020 vs. €16,527/€16,374, respectively. Findings from multivari-
ate sensitivity analyses support the robustness of these preliminary outcomes.
CONCLUSIONS: In the absence of published data, our exploratory economic anal-
ysis provides first indications of potentially lower total first-year costs for initial
CRRT than for IHD/SLEDD. To corroborate these findings, supplementary and con-
sistent clinical and resource use data is warranted.
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OBJECTIVES: Chronic kidney disease (CKD) afflicts up to 26 million people in the
US, but limited information exists about the associated health care costs, especially
in earlier stages of CKD patients with diabetes mellitus (DM). The objective of this
study was to evaluate the medical resource use in US patients diagnosed with CKD
with and without DM. METHODS: A large administrative claims database (Market-
Scan) was used to conduct this retrospective study. Patients aged 18 diagnosed
for CKD between January 1, 2007 to December 31, 2008 with 12 months of contin-
uous pharmaceutical and medical benefit coverage were identified. CKD patients
with DM were defined as receiving a diagnosis code for DM or1 prescription filled
for an antidiabetic medication during the 12-month follow-up period. Multivariate
analysis was conducted controlling for baseline differences between CKD w/DM
and CKD w/o DM cohorts.RESULTS:There were 116,512 patients that met inclusion
criteria with mean age of 65 years and 56% male. Forty-five percent of CKD patients
had a diagnosis for DM during the follow-up period. CKD w/DM had more CKD
related and non-CKD related medical visits in 12 months than CKD w/o DM (12 vs.
9 mean visits, 38 vs. 25 mean visits; all p0.0001). Additionally, adjusted CKD
related medical costs for CKD w/DM were $11,431 annually (p0.0001), compared
to $8,975 for CKD w/o DM. Mean pharmacy costs for CKD w/ DM were also signifi-
cantly higher than CKD w/o DM ($7,206 vs. $5,941, p0.0001). Thus, total mean
adjusted costs (medical & drug) for CKD w/DM were 9% higher than CKD w/o DM
($38,262 vs. $34,759, p0.0001). CONCLUSIONS: In this retrospective study, the
annual medical visits and total healthcare costs were significantly higher for CKD
patients with diabetes compared to CKD patients without comorbid diabetes. This
was particularly evident in the very early and late stages of CKD.
Urinary/Kidney Disorders – Patient-Reported Outcomes & Preference-Based
Studies
PUK13
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OBJECTIVES: Evaluates if modifying the epidemiology of renal disease, more pa-
tients in predialysis and less in dialysis, improves the quality of life Chronic Kidney
Disease (CKD) is a long-term condition described as the gradual loss of kidney
function over time There are various stages of chronic renal failure prior to dialysis
which are also considered as kidney failure. Those in stages III and IV present a
significant percentage of complications from CKD which damage the renal func-
tion and accelerate the need of dialysis. Medical literature suggests early treatment
of renal anemia, proteinuria and hypertension in patients who have not reached
the renal replacement therapy Preventing complications, through adequate care of
known progression factors (diabetes, hypertension, correction of anemia, and pro-
teinuria), of CKD in predialysis stages reduces the progression of renal disease.
Progression of renal damage can be slow down through early intervention preven-
tive treatments such as control of glucose levels, anemia, hypertension and pro-
teinuria in the early stages of the disease.METHODS:We developed a simulation of
1000 patients from predialysis stage coming to dialysis in a period of 30 months.
RESULTS: Without prevention treatment 57% of the patients will require dialysis,
1% will be transplanted and 9.1% will die, while with the prevention treatment only
25% will require dialysis, 0.5% will be transplanted and 4% will die during this
period. CONCLUSIONS: The early treatment of patients provides better quality of
life and significant savings compared with dialysis. Transplantation as a form of
replacement therapy is the best choice for quality life and cost.
Urinary/Kidney Disorders – Health Care Use & Policy Studies
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TRENDS IN RATE AND COST OF HOSPITALIZATIONS DUE TO CHRONIC KIDNEY
DISEASE (CKD) IN THE UNITED STATES
Aggarwal S
Novel Health Strategies, Bethesda, MD, USA
OBJECTIVES: To understand the trends in rate and cost of hospitalizations due to
Chronic Kidney Disease (CKD) in the United States. METHODS: We analyzed last
five years of hospitalizations with ICD-9 diagnosis codes of CKD and End Stage
Renal Disease (ESRD). The annual number of hospitalizations for specific diagnosis
were obtained from AHRQ’s National In-patient Sample (NIS) databases of 2005-
2009. Data were also analyzed for length of stay (LOS), charges and cost of
hospitalization. RESULTS: During last five years the number of hospitalizations
with diagnosis of CKD and ESRD have increased 4.1 and 4.6 fold, respectively. In
2009, an estimated 1,634,422 and 931,641 hospitalizations were with diagnosis of
CKD and ESRD, respectively. The mean LOS for patients with CKD has increased
from 4.9 to 5.5 days, during 2005-2009. The mean LOS for patients with ESRD has
remained steady at 6 days during 2005-2009. The cost of hospitalization with
diagnosis of CKD has increased 31% during 2005-2009. The cost of hospitalization
with diagnosis of ESRD has increased 21% during 2005-2009. In 2009, the mean cost
of hospitalization for patients with CKD and ESRD were $11,209 and $21,358,
respectively. CONCLUSIONS: Hospitalizations due to CKD and ESRD have signifi-
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cantly increased during last five years. There is a need for prevention, treatment
and disease management programs to lower the medical and socioeconomic bur-
den of this disease.
Urinary/Kidney Disorders – Research on Methods
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OBJECTIVES: Secondary hyperparathyroidism (SHPT) is a common condition in
dialysis, characterized by high levels of associated laboratory parameters (LABS):
parathyroid hormone (PTH), serum calcium (Ca) and phosphorous (P). Cinacalcet
can be effective in controlling LABS in SHPT. Objective of this study was to develop
a model to simulate the impact of cinacalcet versus standard treatment (ST) on
patient mortality.METHODS: The model used the latest data on cinacalcet efficacy
in lowering LABS from the OPTIMA and ADVANCE interventional trials together
with the estimated relationship between LABS and mortality from the ARO obser-
vational study on 7970 haemodialysis patients treated in European Fresenius Med-
ical Care facilities. Patient-level data from the 6-month OPTIMA and 12-month
ADVANCE studies were pooled and regression models were fitted with post-treat-
ment values as the response to derive functions predicting 12-month LABS values
from their starting values, patient characteristics and treatment. After 12 months
LABS were assumed constant except for PTH in ST (assumption of a 170 pg/ml per
year increase). Mortality was calculated as that of the dialysis population multi-
plied by relative risks as function of LABS. The model was compared with a Block
observational study analyzing mortality rates (26-month follow-up) in 19,186 hae-
modialysis patients treated at the DaVita dialysis provider in the US. The simula-
tion was run with patient characteristics replicating the DaVita cohort and base
mortality rates from the US Renal Data System. RESULTS: The simulated death
rates (year 1: cinacalcet 18.4%, ST 22.6%, RR0.81; year 2: cinacalcet 32.9%, ST
40.8%, RR0.81) were close to the observed data in the Block study (year 1: cinacal-
cet 15%, ST 20%, RR0.75; year 2: cinacalcet 30%, ST 37%, RR0.81). CONCLUSIONS:
The model showed effects of cinacalcet on mortality similar to those observed in
the DaVita US cohort. This mortality model will be a useful tool for future health-
economic analyses of cinacalcet in SHPT.
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OBJECTIVES: To explore the known-group validity of the Spanish version of the
self-administered OABq-SF questionnaire, which feasibility, reliability and con-
struct and criterion validities have previously been shown. METHODS: The cultur-
ally adapted Spanish version of OABq-SF was administered on two occasions 3
months apart to a set of patients of both genders, 18 years, diagnosed of OAB
according with standard criteria and a score  8 in OAB-V8 scale and able to un-
derstand and filling-in PRO instruments written in Spanish. Patients were recruited
consecutively at clinics of Urology all over the country. Known-groups validity was
explored using the sample of patients classified in quartiles according to their
responses in the OAB-V8 scale at the baseline visit. Patients were compared in the
OABq-SF: symptom bother and HRQoL. For known-group testing purposes, base-
line scores in the OABq-SF questionnaire were used. ANOVA, descriptive statistics
and Pearson=s r coefficients were computed for data analysis. RESULTS: The study
enrolled a total of 246 OAB patients (mean age 57.7 years; 76% women, 99% Cauca-
sian, 37% active workers and 36% primary schooling) at 18 urological. OAB-V8
scores significantly correlated (Pearson=s r coefficient) with OABq-SF domains;
0.790 and0.659 for symptom bother and HRQoL domains, respectively (p0.001
in both cases). Mean (95% CI) of the OABq-SF domain scores were significantly
different between OAB-V8 quartile groups; 39.1 (36.0-42.3), 48.0 (44.5-51.5), 56.7
(53.6-59.8) and 74.6 (71.4-77.7) points for 1st, 2nd, 3rd and 4th quartile groups,
respectively (F10.5, p0.001) in symptom bother domain, and 66.8 (6.1-70.5), 60.5
(56.4-64.6), 53.5 (49.9-57.2) and 37.8 (34.0-41.6) points average score, respectively
(F32.9, p0.001) in HRQoL domain. CONCLUSIONS: The Spanish version of the
OABq-SF instrument provided evidence of known-group validity according with
patient-rated severity of symptom bother in the OAB-V8 scale.
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IMPROVING PATIENT SAFETY IN THE UK AND ENGAGING PATIENTS IN
RESEARCH: A NEW MODEL FOR THE NHS?
Cascade E1, Collier D2, Kula-Przezwanski C3
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OBJECTIVES:The purpose of this study was to determine awareness of and interest
in research amongst members of a web-based medicines monitoring service and to
solicit opinions on whether this service should be offered by the NHS. METHODS:
In May 2011, we surveyed 150 uk.MediGuard.org members: 50 in England, Scotland,
and Wales. uk.MediGuard.org is a free medicines monitoring service covering over
2.5 million patients, including 100,000 in the UK. RESULTS: Ninety-one percent of
respondents rate the MediGuard service as good or excellent and 99% are unaware
of similar services in the UK. When asked whether the National Health Service
(NHS) should introduce MediGuard to all patients, 93% responded yes and 89% said
that offering the service would positively impact their impression of the NHS (43%
significantly, 46% somewhat positive impact). While only 12% have ever enrolled in
a trial, 71% were at least somewhat interested in participating in the next 12
months (23% extremely, 17% very, 31% somewhat interested). The primary reason
why patients have not enrolled in a trial is lack of awareness (68%); only 16%
mentioned lack of participation due to concerns about an experimental drug.
CONCLUSIONS: Survey results show that engagement in a medicines monitoring
service is an effective method for improving outcomes and increasing awareness of
clinical trials; pilot studies are now underway. Historically, the NHS has been slow
to pursue public-private partnerships, however, NHS efforts to stimulate on-line
patient engagement have not been a huge success (e.g., HealthSpace enrolled 3,000
in the first year at a cost of £8 million). Recognizing that all UK countries have
initiatives to increase participation in research, perhaps it is time for the NHS to
reconsider the role of partnerships to leverage the explosion of web-based appli-
cations as a method for stimulating research.
PHP2
RELATION BETWEEN CONSUMER BEHAVIOUR AND DRUG SAFETY
MONITORING IN FRANCE
Furet J1, Genane C2, Ando G3, Marinoni G2
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OBJECTIVES: This study aimed to assess the opinion of the French population on
the publication of a list of 77 medicines under regulatory monitoring (surveillance
list, published following market withdrawal of diet adjuvant benfluorex) in France
and more specifically evaluate its impact on consumer behaviour. METHODS: A
total of 928 French individuals answered a phone questionnaire consisting of 37
closed questions and 3 open-ended questions. Respondents were aged 30 and over
since this age group is expected to be more prone to diseases and chronic pathol-
ogies. The study, carried out in March 2011, was compliant with the French Na-
tional INSEE quota methodology. RESULTS: Around 7% of the sample population
declared using at least one of the products included in the French surveillance list.
Of these, over one in three persons indicated their intention to stop or suspend
their treatment in reaction to their medicine’s regulatory surveillance while one in
three persons did not intend to change their treatment intake. Meanwhile, in the
larger study sample, nearly one in six persons declared considering reducing their
medicine purchasing patterns as a result of the surveillance list publication, a
figure in line with studies conducted prior to the publication of the list. Finally,
treatment compliance was reported at 85.8% pre-surveillance list publication and
83.5% post-surveillance list publication. CONCLUSIONS: French consumer confi-
dence in pharmaceuticals in general is mostly unaffected by the new surveillance
list. However, consumer behaviour is strongly affected by product inclusion onto
the surveillance list, especially for those patients treated with at least one listed
treatment. Furthermore, consumer confidence in healthcare regulators, off-label
prescribing and pharmaceutical companies was negatively affected by the benfluo-
rex case. Prescribers will have a pivotal role in maintaining overall confidence
through patient communication and information.
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PATIENT PREFERENCES CONSIDERING THE CHOICE OF HEALTH CARE
PROVIDERS IN HUNGARY– RESULTS FROM DISCRETE CHOICE EXPERIMENT
Baji P1, Pavlova M1, Gulacsi L2, Groot W1
1Maastricht University, Maastricht, The Netherlands, 2Corvinus University Budapest, Budapest,
Hungary
OBJECTIVES:We use discrete choice experiment to analyze which attributes (qual-
ity, access, and price) influence patients’ choice between health care providers. We
also estimate the willingness-to-pay of respondents for the improvement of health
care characteristics. METHODS: Data was collected via household survey con-
ducted by face-to-face interviews in Hungary, 2010. Respondents were selected
based on multistage random probability method. In total, 1037 respondents filled in
the questionnaire. In DCE, eight choice set for the physician and eight for hospital
services were presented to the respondents in the form of alternative and basic
profiles that contained combinations of attributes of health care services. Attri-
butes and attribute levels were developed on the basis of literature review. For the
analysis binary probit regression with random effects was used including attribute
differences as well as interactions of attribute differences and socio-economic
characteristic as independent variables. Marginal rates of substitution (MRS) were
calculated to indicate the willingness-to-pay of the respondent for the improve-
ments in the attribute levels. RESULTS: The response rate of the survey was 67%.
Significant negative regression coefficients (p0.1) of the interactions between
price and social economic characteristics show that respondents from a village or
the capital, with low education and bad health status were more sensitive to
changes in the price attribute when choosing between health care providers. MRSs
show that respondents are willing to pay the most for the good skills and reputa-
tion of the physician and the attitude of the personnel, followed by modern equip-
ments and maintenance of the office/hospital. Access attributes (travelling and
waiting time in front of the office) were less important. CONCLUSIONS: DCE
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